Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
Authors
Mohr-Holland, EReuter, A
Hughes, J
Daniels, J
Beko, B
Makhanda, G
De Avezedo, V
Kock, Y
Cox, H
Furin, J
Trivino Duran, L
Isaakidis, P
Ferlazzo, G
Issue Date
2020-07-23Submitted date
2020-10-06
Metadata
Show full item recordJournal
The European Respiratory JournalPublisher
European Respiratory SocietyPubMed ID
32703820Type
OtherLanguage
enDescription
We regret that this article is behind a paywall.EISSN
1399-3003ae974a485f413a2113503eed53cd6c53
10.1183/13993003.00837-2020
Scopus Count
Collections
Related articles
- Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
- Authors: Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P
- Issue date: 2018 May
- Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
- Authors: Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, De Azevedo V, Kock Y, Steele SJ, Shroufi A, Ade S, Alikhanova N, Benedetti G, Edwards J, Cox H, Furin J, Isaakidis P
- Issue date: 2018 Jun
- Bedaquiline or delamanid for rifampin-resistant tuberculosis?
- Authors: Lessem E, Cox V, Furin J
- Issue date: 2017 Oct
- Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.
- Authors: Tadolini M, Tiberi S, Migliori GB
- Issue date: 2018 May
- Six-Month Response to Delamanid Treatment in MDR TB Patients.
- Authors: Hewison C, Ferlazzo G, Avaliani Z, Hayrapetyan A, Jonckheere S, Khaidarkhanova Z, Mohr E, Sinha A, Skrahina A, Vambe D, Vasilyeva I, Lachenal N, Varaine F
- Issue date: 2017 Oct